When the antihypertensive effect of bisoprolol fumarate is not as expected, other antihypertensive drugs, such as lercanidipine hydrochloride, need to be used in combination to enhance the antihypertensive effect, but the dose may need to be adjusted. Bisoprolol fumarate belongs to β1 receptor blocker, mainly through slowing down the heart rate, weakening myocardial contractility to achieve the effect of lowering blood pressure and anti-angina. It can also be used in the treatment of heart failure in the stable phase. It maintains the function of the heart by inhibiting cardiac remodeling and slows down the rate of heart failure. Lercanidipine is a new generation of dihydropyridine calcium channel blocker, with strong vascular selectivity, smooth onset of action, strong antihypertensive effect, long duration of action, and small negative inotropic effect. It is used for the treatment of mild and moderate essential hypertension. When Lercanidipine and metoprolol (a beta-adrenergic receptor blocker cleared mainly by the liver) were applied together, there was no significant change in the bioavailability of metoprolol, but the bioavailability of Lercanidipine decreased by 50%. This effect may be due to the fact that beta-adrenergic receptor blockers reduce blood flow to the liver and thus may have a similar effect on other drugs in this class. Therefore, Lercanidipine can be safely taken concomitantly with beta-adrenergic receptor blockers, but dosage adjustments may be necessary. Adverse effects such as mild fatigue, dizziness, and headache are occasionally seen with bisoprolol fumarate and are contraindicated in patients with acute heart failure; adverse effects such as elevated aminotransferases, hypotension, frequent urination, and chest pain are occasionally seen with leucodipine hydrochloride tablets, and this medication is contraindicated during pregnancy and lactation. Bisoprolol fumarate and Lercanidipine Hydrochloride should be taken at the same time, should be under the guidance of a doctor.